Lupin Recognized Among India's Best Employers in Nation-Builders Category by Great Place To Work® India 2026
Mumbai: Global pharmaceutical major Lupin Limited has been recognized among India's Best Employers in the Nation Builders Category 2026 by Great Place To Work® India. The company ranked among the Top 14 organizations nationally for this distinction, which highlights its dedication to fostering a culture rooted in purpose, trust, and inclusion while making meaningful societal contributions.The Nation Builders category acknowledges organizations whose influence extends past standard business performance. It specifically recognizes those that contribute to employment, community advancement, people development, and nation-building, alongside cultivating exceptional workplace cultures.
Yashwant Mahadik, President - Global Human Resources at Lupin, commented on the achievement. He stated that the recognition celebrates the culture that their employees bring daily. At Lupin, the focus is on building an environment where individuals feel supported and empowered, connected to a shared purpose. By investing in its people and their growth, the company aims to create a workplace that enables significant contributions toward patients, communities, and society.
Organizations selected for this category undergo a rigorous, independent assessment conducted by Great Place To Work® India. The selection process is based on the Trust Index™, which evaluates employee experience, Culture Audit™ findings of people practices, and eligibility criteria assessing an organization's wider contribution to nation-building.
Lupin Limited operates as a global pharmaceutical leader headquartered in Mumbai, with products distributed across more than 100 markets. The company specializes in various pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Lupin maintains a strong presence in India and the U.S. across several therapy areas, such as cardiovascular, anti-diabetic, respiratory, gastrointestinal, central nervous system, and women's health.
The company maintains 15 state-of-the-art manufacturing sites and 7 research centers globally, supported by a workforce exceeding 26,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries: Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
LUPIN Stock Price Movement
Shares of Lupin Limited are edging higher to ₹2496.7 as of 9:29 AM, having gained 0.16% in live trading with a change of ₹4.10. The equity has seen a traded volume of 13,259 shares so far this morning.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.